-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120

Benzinga·07/13/2026 10:24:04
語音播報
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $110 to $120.